Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Fox Corp Class A (FOXA) vs Novo Nordisk A/S (NVO) Price & Performance

Fox Corp Class ATrade
Novo Nordisk A/STrade

Price performance (Past 24H)

Key statistics

Fox Corp Class A vs Novo Nordisk A/S — how do they compare? Fox Corp Class A trades at $62.01 (market cap $24.58B), while Novo Nordisk A/S trades at $46.25 (market cap $207.85B). The key difference: Novo Nordisk A/S is far larger — about 8.5× Fox Corp Class A's market cap, and Novo Nordisk A/S pays the higher dividend (3.81%). Which is the better fit depends on your goals.

FOXANVO
Market Cap
$24.58B$207.85B
Sector
MediaHealth
52-Week High
$76.11$63.98
52-Week Low
$48.79$35.29
Enterprise Value
$27.94B$222.55B
Dividend Yield
0.93%3.81%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Fox Corp Class A

FOXA stock trades at $61.69, down 2.74% today, amid a bullish technical setup with strong support at $60. The company reported robust Q4 2026 results, beating earnings estimates with $1.79 EPS versus $1.44 expected, driven by World Cup advertising and Tubi streaming growth. Revenue rose 28% year-over-year to $4.21 billion in the quarter. Analyst sentiment is evenly split between Buy and Hold ratings, with a consensus price target of $65.33.

The outlook remains positive given strong ad demand and digital momentum, but risks include higher sports costs and reliance on major events. Earnings growth and streaming execution are key catalysts for further upside, though valuation multiples appear reasonable with a P/E of 16.18.

Novo Nordisk A/S

Novo Nordisk (NVO) trades at $46.28, down 3.05% today, with technical indicators showing neutral signals. The company maintains strong fundamentals with Q2 2026 EPS beating expectations at $0.96 versus $0.77 estimate, continuing a pattern of earnings outperformance. Revenue growth remains solid with 2025 revenue reaching $309.1B and net income margin of 33.14%. Analyst sentiment remains positive with 57.9% recommending Buy, though recent news highlights competitive pressures from Eli Lilly in the GLP-1 market.

NVO presents a compelling investment case with robust profitability metrics including 59.82% ROE and attractive valuation at 11.62 P/E. However, increasing competition in weight-loss drugs and pricing pressures create headwinds. The stock's current technical neutrality suggests potential consolidation near current levels, with fundamental strength supporting long-term growth prospects despite near-term competitive challenges.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Fox Corp Class A

Fox operates in cable networks and television. Its cable segment includes Fox News, Fox Business, and sports channels, while its TV segment covers the Fox network, 29 local stations (18 Fox-affiliated), and the ad-supported streaming service Tubi. After selling most of its entertainment assets to Disney in 2019, Fox now focuses on live news and sports, primarily within pay-TV. The Murdoch family controls the company.

Read more on FOXA

About Novo Nordisk A/S

With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.

Read more on NVO